Intervacc is trading 5.6% up today at SEK 1.35. The move follows the company's submission of a Type II variation application to the European Medicines Agency (EMA) for Strangvac, seeking to extend its duration of immunity to 12 months. Additionally, Intervacc recently announced its first export of Strangvac to New Zealand under a Special Circumstances Permit. These regulatory and market expansion developments are likely contributing to the positive sentiment.